Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Inhibition of casein kinase 2 induces cell death in tyrosine kinase inhibitor resistant chronic myelogenous leukemia cells

O. Mitrovský, D. Myslivcová, T. Macháčková-Lopotová, A. Obr, K. Čermáková, Š. Ransdorfová, J. Březinová, H. Klamová, M. Žáčková

. 2023 ; 18 (5) : e0284876. [pub] 20230504

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23011492

Chronic myelogenous leukemia (CML) is a myeloproliferative disease characterized by the BCR-ABL oncogene. Despite the high performance of treatment with tyrosine kinase inhibitors (TKI), about 30% of patients develop resistance to the therapy. To improve the outcomes, identification of new targets of treatment is needed. Here, we explored the Casein Kinase 2 (CK2) as a potential target for CML therapy. Previously, we detected increased phosphorylation of HSP90β Serine 226 in patients non-responding to TKIs imatinib and dasatinib. This site is known to be phosphorylated by CK2, which was also linked to CML resistance to imatinib. In the present work, we established six novel imatinib- and dasatinib-resistant CML cell lines, all of which had increased CK2 activation. A CK2 inhibitor, CX-4945, induced cell death of CML cells in both parental and resistant cell lines. In some cases, CK2 inhibition also potentiated the effects of TKI on the cell metabolic activity. No effects of CK2 inhibition were observed in normal mononuclear blood cells from healthy donors and BCR-ABL negative HL60 cell line. Our data indicate that CK2 kinase supports CML cell viability even in cells with different mechanisms of resistance to TKI, and thus represents a potential target for treatment.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23011492
003      
CZ-PrNML
005      
20230801133101.0
007      
ta
008      
230718s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0284876 $2 doi
035    __
$a (PubMed)37141212
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Mitrovský, Ondřej $u Department of Proteomics, Institute of Hematology and Blood Transfusion, Prague 2, Czech Republic $u Faculty of Science, Charles University, Prague, Czech Republic
245    10
$a Inhibition of casein kinase 2 induces cell death in tyrosine kinase inhibitor resistant chronic myelogenous leukemia cells / $c O. Mitrovský, D. Myslivcová, T. Macháčková-Lopotová, A. Obr, K. Čermáková, Š. Ransdorfová, J. Březinová, H. Klamová, M. Žáčková
520    9_
$a Chronic myelogenous leukemia (CML) is a myeloproliferative disease characterized by the BCR-ABL oncogene. Despite the high performance of treatment with tyrosine kinase inhibitors (TKI), about 30% of patients develop resistance to the therapy. To improve the outcomes, identification of new targets of treatment is needed. Here, we explored the Casein Kinase 2 (CK2) as a potential target for CML therapy. Previously, we detected increased phosphorylation of HSP90β Serine 226 in patients non-responding to TKIs imatinib and dasatinib. This site is known to be phosphorylated by CK2, which was also linked to CML resistance to imatinib. In the present work, we established six novel imatinib- and dasatinib-resistant CML cell lines, all of which had increased CK2 activation. A CK2 inhibitor, CX-4945, induced cell death of CML cells in both parental and resistant cell lines. In some cases, CK2 inhibition also potentiated the effects of TKI on the cell metabolic activity. No effects of CK2 inhibition were observed in normal mononuclear blood cells from healthy donors and BCR-ABL negative HL60 cell line. Our data indicate that CK2 kinase supports CML cell viability even in cells with different mechanisms of resistance to TKI, and thus represents a potential target for treatment.
650    _2
$a lidé $7 D006801
650    _2
$a imatinib mesylát $x farmakologie $7 D000068877
650    12
$a kaseinkinasa II $7 D047390
650    _2
$a inhibitory tyrosinkinasy $7 D000092004
650    _2
$a dasatinib $x farmakologie $7 D000069439
650    _2
$a bcr-abl fúzní proteiny $x metabolismus $7 D016044
650    _2
$a chemorezistence $7 D019008
650    _2
$a apoptóza $7 D017209
650    _2
$a inhibitory proteinkinas $x farmakologie $7 D047428
650    12
$a chronická myeloidní leukemie $x farmakoterapie $7 D015464
650    _2
$a buněčná smrt $7 D016923
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Myslivcová, Denisa $u Department of Proteomics, Institute of Hematology and Blood Transfusion, Prague 2, Czech Republic
700    1_
$a Macháčková-Lopotová, Tereza $u Department of Proteomics, Institute of Hematology and Blood Transfusion, Prague 2, Czech Republic
700    1_
$a Obr, Adam $u Department of Proteomics, Institute of Hematology and Blood Transfusion, Prague 2, Czech Republic $1 https://orcid.org/000000030057076X
700    1_
$a Čermáková, Kamila $u Laboratory of PCR Diagnostics of Leukemias, Institute of Hematology and Blood Transfusion, Prague 2, Czech Republic
700    1_
$a Ransdorfová, Šárka $u Department of Cytogenetics, Institute of Hematology and Blood Transfusion, Prague 2, Czech Republic
700    1_
$a Březinová, Jana $u Department of Cytogenetics, Institute of Hematology and Blood Transfusion, Prague 2, Czech Republic
700    1_
$a Klamová, Hana $u Clinical Division, Institute of Hematology and Blood Transfusion, Prague 2, Czech Republic
700    1_
$a Žáčková, Markéta $u Department of Proteomics, Institute of Hematology and Blood Transfusion, Prague 2, Czech Republic
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 18, č. 5 (2023), s. e0284876
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37141212 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801133057 $b ABA008
999    __
$a ok $b bmc $g 1963728 $s 1197757
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 18 $c 5 $d e0284876 $e 20230504 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20230718

Najít záznam

Citační ukazatele

Možnosti archivace